J&J’s neuroscience renaissance? Janssen R&D chief readying for 'golden age'
J&J’s Janssen neuroscience division has been a solid revenue contributor focused mostly on psychiatric drugs — but now its portfolio is headed for a change.
Bill Martin, Janssen’s global head of neuroscience for research and development now for 18 months, is looking to build out precision products as neuroscience “enters a golden age.”
The pharma is now “expanding our commercial portfolio beyond psychiatry and introducing new therapies across neurological neurodegenerative and autoantibody driven diseases,” he said in an interview with Endpoints MarketingRx.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.